Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review.
Ilfita SahbudinRuchir SinghJeanette TrickeyAliaksandra BaranskayaAlexander TracyKarim RazaAndrew FilerSue JowettAnnelies BoonenPublished in: Rheumatology advances in practice (2023)
The association between symptom/disease duration at the time of DMARD initiation and resource utilization/cost in patients with RA remains unclear. Health economic modelling with clearly defined symptom duration, resource utilization and long-term productivity is vital to address this evidence gap.
Keyphrases
- patient reported
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- healthcare
- public health
- chronic kidney disease
- mental health
- disease activity
- climate change
- prognostic factors
- peritoneal dialysis
- stem cells
- ankylosing spondylitis
- interstitial lung disease
- systemic sclerosis
- bone marrow
- social media
- health information
- risk assessment